Association of genetic variation in adaptor protein APPL1/APPL2 loci with non-alcoholic fatty liver disease

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Barbieri, Michelangela ^a   Esposito, Antonietta ^a   Angellotti, Edith ^a   Rizzo, Maria Rosaria ^a   Marfella, Raffaele ^a   Paolisso, Giuseppe ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; TRIACYLGLYCEROL; ADIPONECTIN RECEPTOR; ADIPOQ PROTEIN, HUMAN; APPL1 PROTEIN, HUMAN; APPL2 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; APPL1 GENE; APPL2 GENE; ARTICLE; BODY FAT; BODY FAT DISTRIBUTION; BODY MASS; CARDIOVASCULAR RISK; CELL PROTECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FATTY LIVER; FEMALE; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INSULIN RESISTANCE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PROTEIN FUNCTION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BLOOD; CASE CONTROL STUDY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADIPONECTIN; ADULT; AGED; ALANINE TRANSAMINASE; ALLELES; CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; GENE FREQUENCY; GENETIC LOCI; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADIPONECTIN; SEVERITY OF ILLNESS INDEX;

EID: 84925032273     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071391     Document Type: Article

References (38)

1. Farrell GC, Larter CZ (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43: S99-S112.
2. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, et al. (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42: 44-52.
3. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E (2010) The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 12(5): 365-83.
4. Polyzos SA, Kountouras J, Zavos C (2009) Non alcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 72: 299-314.
5. Musso G, Gambino R, Durazzo M, Biroli G, Carello M, et al. (2005) Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepathology 42: 1175-1183.
6. Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, et al. (2006) Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 64(6): 679-83.
7. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762-769.
8. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, et al. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288-1295.
9. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, et al. (2006) APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 8: 516-523.
10. Deepa SS, Dong LQ (2009) APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab 296(1): E22-E36.
11. Wang Y, Cheng KK, Lam KS, Wu D, Wang Y, et al. (2011) APPL1 counteracts obesity-induced vascular insulin resistance and endothelial dysfunction by modulating the endothelial production of nitric oxide and endothelin-1 in mice. Diabetes 60(11): 3044-54.
12. Cheng KK, Lam KS, Wang Y, Huang Y, Carling D, et al. (2007) Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes 56: 1387-1394.
13. Cheng KK, Iglesias MA, Lam KS, Wang Y, Sweeney G, et al. (2009) APPL1 potentiates insulin-mediated inhibition of hepatic glucose production and alleviates diabetes via Akt activation in mice. Cell Metab 9: 417-42.
14. Hosch SE, Olefsky JM, Kim JJ (2006) APPLied mechanics: uncovering how adiponectin modulates insulin action. Cell Metab 4(1): 5-6.
15. Wang C, Xin X, Xiang R, Ramos FJ, Liu M, et al. (2009) Yin-Yang regulation of adiponectin signaling by APPL isoforms in muscle cells. J Biol Chem 284(46): 31608-31615.
16. Suzuki A, Lindor K, St Saver J, Lymp J, Mendes F, et al. (2005) Effect of changes on body weight and lifestyle in non-alcoholic fatty liver disease. J Hepatol 43, 1060-1066.
17. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, et al. (2011) Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7: e1001324.
18. Song J, da Costa KA, Fischer LM, Kohlmeier M, Kwock L, et al. (2005) Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J 19: 1266-1271.
19. Sookoian S, Castaño G, Gianotti TF, Gemma C, Rosselli MS, et al (2008) Genetic variants in STAT3 are associated with nonalcoholic fatty liver disease. Cytokine 44: 201-206.
20. Tokushige K, Hashimoto E, Noto H, Yatsuji S, Taniai M, et al. 2009 Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease. J Gastroenterol 44, 976-98.
21. Li Y, Xing C, Cohen JC, Hobbs HH (2012) Genetic variant in PNPLA3 is associated with nonalcoholic fatty liver disease in China. Hepatology 55: 327-328.
22. Fang QC, Jia WP, Gao F, Zhang R, Hu C, et al. (2008) Association of variants in APPL1 gene with body fat and its distribution in Chinese patients with type 2 diabetic mellitus. Zhonghua Yi Xue Za Zhi 88(6): 369-373.
23. Staiger H, Machicao F, Machann J, Schick F, Kuulasmaa T, et al. (2007) Genetic variation within the APPL locus is not associated with metabolic or inflammatory traits in a healthy White population. Diabet Med 24: 817-822.
24. Jiang S, Fang Q, Yu W, Zhang R, Hu C, et al. (2012) Genetic variations in APPL2 are associated with overweight and obesity in a Chinese population with normal glucose tolerance. BMC Medical Genetics 30: 13-22.
25. Ma XW, Ding S, Ma XD, Gu N, Guo XH (2011) Genetic variability in adapter proteins with APPL1/2 is associated with the risk of coronary artery disease in type 2 diabetes mellitus in Chinese Han population. Chin Med J (Engl). Nov;124(22): 3618-21.
26. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142 (7): 1592-609.
27. Zeng MD, Fan JG, Lu LG, Li YM, Chen CW, et al. (2008) Chinese National Consensus Workshop on Nonalcoholic Fatty Liver Disease. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis 9(2): 108-12.
28. Loria P, Adinolfi LE, Bellentani S, Bugianesi E, Grieco A, et al (2010) Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee Dig Liver Dis 42(4): 272-82.
29. Saverymuttu SH, Joseph AE, Maxwell JD (1986) Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 292(6512): 13-5.
30. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, et al (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23: 57-63.
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-9.
32. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL (2004) A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm. Ann Hum Genet 68 (Pt 2): 165-77.
33. Li YY (2012) Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. World J Gastroenterol 18(45): 6546-51.
34. Choudhury J, Sanyal AJ (2004) Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 8: 575-94.
35. Saito T, Jones CC, Huang S, Czech MP, Pilch PF (2007) The interaction of Akt with APPL1 is required for insulin-stimulated Glut4 translocation. J Biol Chem 282: 32280-32287.
36. Nechamen CA, Thomas RM, Dias JA (2007) APPL1, APPL2, Akt2 and FOXO1a interact with FSHR in a potential signaling complex. Mol Cell Endocrinol 260-262: 93-99.
37. Chial HJ, Wu R, Ustach CV, McPhail LC, Mobley WC, et al (2008) Membrane targeting by APPL1 and APPL2: dynamic scaffolds that oligomerize and bind phosphoinositides. Traffic 9(2): 215-229.
38. Puppala J, Siddapuram SP, Akka J, Munshi A (2013) Genetics of nonalcoholic Fatty liver disease: an overview. J Genet Genomics 40(1): 15-22.